Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

Hallym University Medical Center1 site in 1 country38 target enrollmentJanuary 2008

ConditionsCentral Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity
Sponsor: Hallym University Medical Center
Enrollment: 38
Locations: 1
Primary Endpoint: best corrected visual acuity
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Registry

clinicaltrials.gov

Start Date

January 2008

End Date

January 2010

Last Updated

16 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Hallym University Medical Center

Eligibility Criteria

Inclusion Criteria

•central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion

Exclusion Criteria

•previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
•Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
•neovascularization on the disc or elsewhere or rubeosis